A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020; 72: 67A-68A. abstract 90.
- Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double- blind, placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationTacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationTirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Self-citationHepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“The pan-PPAR agonist lanifibranor demonstrated antifibrotic efficacy in mouse models 199,225 as well as in a phase IIb trial in 247 patients with active NASH 201 , prompting its further evaluation in a phase III clinical trial (NCT04849728) 226 .”
BackgroundDuell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Kaplan, D. E., Ripoll, C., Thiele, M., Fortune, B. E., Simonetto, D. A., Garcia-Tsao, G., & Bosch, J. (2024) · Hepatology · doi:10.1097/hep.0000000000000647 · Cited by 486
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
“In a recent phase 2b clinical study, lanifibranor not only showed good tolerability but also significantly improved liver fibrosis in NASH patients.(404) Lanifibranor improved NASH may be partially related to lowering cholesterol.”
BackgroundNon-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Self-citationXu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
“In a clinical 2b trial (NCT03008070), Lanifibranor achieved optimal results that patients treated with the 1200-mg dose of Lanifibranor had a decrease of at least two points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis (SAF) scoring system) without worsening of fibrosis and reached the pr…”
MethodVerrastro, O., Panunzi, S., Castagneto-Gissey, L., De Gaetano, A., Lembo, E., Capristo, E., Guidone, C., Angelini, G., Pennestrì, F., Sessa, L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00634-7 · Cited by 362
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Self-citationMetabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationCurrent treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2026) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 221
Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276
Self-citationPathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Le, P., Tatar, M., Dasarathy, S., Alkhouri, N., Herman, W. H., Taksler, G. B., Deshpande, A., Ye, W., Adekunle, O. A., McCullough, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54707 · Cited by 243
Self-citationHutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Macrophage functional diversity in NAFLD — more than inflammation
Barreby, E., Chen, P., & Aouadi, M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00675-6 · Cited by 247
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal-Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 222
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 199
“In a phase IIb study, Lanifibranor was effective in reducing NASH fibrosis, liver enzyme levels inflammatory, and fibrosis biomarkers.(154)”
NAFLD and NASH: etiology, targets and emerging therapies
Wei, S., Wang, L., Evans, P. C., & Xu, S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103910 · Cited by 212
Microbiome-derived ethanol in nonalcoholic fatty liver disease
Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02016-6 · Cited by 215
“Transcriptomic analyses of the liver showed differences between NAFLD classes in processes including one-carbon metabolism, PPAR signaling and apoptosis, as reported in the literature 6,17,18 .”
Self-citationFeng, G., Valenti, L., Wong, V. W.-S., Fouad, Y. M., Yilmaz, Y., Kim, W., Sebastiani, G., Younossi, Z. M., Hernandez-Gea, V., & Zheng, M.-H. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00846-4 · Cited by 198
“For example, fibrosis regression was also reported in clinical trials using obeticholic acid and lanifibranor in patients with NASH 50,51 .”
Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
“Lanifibranor (a pan-PPAR agonist) [246] and fibroblast growth factor-21 analogues (e.g., efruxifermin and pego-zafermin) have also shown promising results in early-stage clinical trials, while phase 3 studies are underway [247, 248].”
Tang, S.-P., Mao, X.-L., Chen, Y.-H., Yan, L.-L., Ye, L.-P., & Li, S.-W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870239 · Cited by 184
“lowered the SAF-A score and relieved NASH in a recently published Phase 2b randomized, double-blind, placebocontrolled trial (115).”
BackgroundTherapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“As a result, a phase III clinical trial is underway (NCT04849728) 152 .”
Current therapies and new developments in NASH
Dufour, J.-F., Anstee, Q. M., Bugianesi, E., Harrison, S., Loomba, R., Paradis, V., Tilg, H., Wong, V. W.-S., & Zelber-sagi, S. (2022) · Gut · doi:10.1136/gutjnl-2021-326874 · Cited by 190
Self-citationChew, N. W. S., Mehta, A., Goh, R. S. J., Zhang, A., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A., Dimitriadis, G. K., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 167
“79 Studies have highlighted the ability of lani-fibranor to decrease liver and muscle insulin resistance, as well as improve unfavorable cardiometabolic profile (eg, hyperglycemia, hyperlipidemia, and high diastolic blood pressure) in indivduals with MASLD.”
Self-citationGovaere, O., Petersen, S. K., Martinez-Lopez, N., Wouters, J., Van Haele, M., Mancina, R. M., Jamialahmadi, O., Bilkei-Gorzo, O., Lassen, P. B., Darlay, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.012 · Cited by 165
Self-citationSteatotic liver disease, MASLD and risk of chronic kidney disease
Bilson, J., Mantovani, A., Byrne, C. D., & Targher, G. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101506 · Cited by 166
“These data showed that the percentage of patients with improvement of at least two points in the histologic SAF score (steatosis, activity, and fibrosis) without worsening of fibrosis was significantly greater among those treated with the 1200-mg dose of lanifibranor than with placebo [114].”
Zhou, X.-D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K.-C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L.-L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01697-0 · Cited by 168
“In the phase 2B placebocontrolled NATIVE trial [103], the histological SAF-A (activity of liver steatosis, activity, and fibrosis) score was reduced in obese patients with biopsy-confirmed nonalcoholic steatohepatitis.”
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD
Clare, K., Dillon, J. F., & Brennan, P. N. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00067 · Cited by 150
Sangro, P., de la Torre‐Aláez, M., Sangro, B., & D’Avola, D. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00954-4 · Cited by 179
“%) were observed [43].”
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 180
“[228].”
BackgroundTodisco, S., Santarsiero, A., Convertini, P., Stefano, G. D., Gilio, M., Iacobazzi, V., & Infantino, V. (2022) · Biology · doi:10.3390/biology11050792 · Cited by 180
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Li, M., Wang, M., Wen, Y., Zhang, H., Zhao, G., & Gao, Q. (2023) · MedComm · doi:10.1002/mco2.349 · Cited by 187
Newsome, P. N., Sanyal, A. J., Engebretsen, K. A., Kliers, I., Østergaard, L., Vanni, D., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18331 · Cited by 145
“The enrolment of participants into MASH clinical trials is challenging with 65%–87% of screened participants not meeting eligibility criteria [20–22].”
Self-citationHarrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 142
Self-citationLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Clinical Trial Landscape in NASH
Harrison, S. A., Loomba, R., Dubourg, J., Ratziu, V., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.041 · Cited by 137
Self-citationTherapeutic management of metabolic dysfunction associated steatotic liver disease
Zeng, J., Fan, J., & Francque, S. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12525 · Cited by 151
“Other promising drugs, based on Phase 2 data, include the panPPAR agonist lanifibranor, 40 the GLP ‐ 1RA receptor agonist semaglutide, 26 both in ongoing Phase 3 trials (Table 1), as well as the fibroblast growth factor 21 agonist pegozafermin 41 that recently reported beneficial effects on…”
BackgroundSelf-citationNon‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 159
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Tincopa, M. A., Anstee, Q. M., & Loomba, R. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.011 · Cited by 126
Self-citationBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Self-citationTranscriptional control of energy metabolism by nuclear receptors
Scholtes, C., & Giguère, V. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00486-7 · Cited by 141
Li, Q., Liu, W., Zhang, H., Chen, C., Liu, R., Hou, H., Luo, Q., Yu, Q., Ouyang, H., Feng, Y., et al. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.120197 · Cited by 135
Miller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 153
Metabolic dysfunction-associated steatotic liver disease and the heart
Driessen, S., Francque, S., Anker, S. D., Cabezas, M. C., Grobbee, D. E., Tushuizen, M. E., & Holleboom, A. G. (2023) · Hepatology · doi:10.1097/hep.0000000000000735 · Cited by 151
“Lanifibranor, a balanced pan-PPAR agonist, was the first drug to show a significant effect on both the resolution of MASH and improvement of fibrosis in a phase Ⅱ b trial, [148] and a phase Ⅲ trial is currently underway (ClinicalTrials.gov Identifier: NCT04849728).”
Self-citationHabibullah, M., Jemmieh, K., Ouda, A., Haider, M. Z., Malki, M. I., & Elzouki, A.-N. Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1291501 · Cited by 137
“An example of such a drug is Lanifibranor, a pan-PPAR (peroxisome proliferator–activated receptor) agonist, which affects crucial metabolic, inflammatory, and fibrogenic processes in NASH development (110).”
Gallage, S., Ali, A., Barragan Avila, J. E., Seymen, N., Ramadori, P., Joerke, V., Zizmare, L., Aicher, D., Gopalsamy, I. K., Fong, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.015 · Cited by 118
Ratziu, V., Scanlan, T. S., & Bruinstroop, E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.018 · Cited by 128
Self-citationObesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
Choi, W., Woo, G. H., Kwon, T., & Jeon, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199715 · Cited by 130
“…address mitochondrial dysfunction + inflammation, lanifibranor (pan-PPAR) upregulates β -oxidation and PGC-1 α through PPAR-α / δ while repressing inflammatory transcription via PPAR-γ ; in the phase-2b NATIVE RCT it achieved both MASH resolution and ≥ 1-stage fibrosis improvement [240].”
Lau, H. C.-H., Zhang, X., & Yu, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01089-1 · Cited by 138
Treating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 108
Self-citationde Souza, M. H. G., Al‐Sharif, L., Antunes, V., Huang, D. Q., & Loomba, R. (2025) · Hepatology · doi:10.1097/hep.0000000000001254 · Cited by 124
Self-citationQi, X., Li, J., Caussy, C., Teng, G., & Loomba, R. (2026) · Hepatology · doi:10.1097/hep.0000000000000913 · Cited by 131
“[66]”
Self-citationByrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 136
“The pan-peroxisome proliferator-activated receptor (PPAR) agonist lanifibranor 127 showed a dose-dependent histological improvement in steatohepatitis and fibrosis in a phase IIb trial with 247 individuals with non-cirrhotic MASH, retaining a beneficial effect on glucose and lipid metabolism as…”
Self-citationHarrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100563 · Cited by 110
Self-citationROS/RNS as molecular signatures of chronic liver diseases
Che, Z., Zhou, Z., Li, S.-Q., Gao, L., Xiao, J., & Wong, N.-K. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.001 · Cited by 110
Mellemkjær, A., Kjær, M. B., Haldrup, D., Grønbæk, H., & Thomsen, K. L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.11.012 · Cited by 118
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 124
Self-citationHou, T., Tian, Y., Cao, Z., Zhang, J., Feng, T., Tao, W., Sun, H., Wen, H., Lu, X., Zhu, Q., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.018 · Cited by 112
Huang, S., & Liu, C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0422 · Cited by 122
“Lanifibranor, a pan-peroxisome proliferatoractivated receptor agonist, achieved the endpoints of resolution of NASH and reversal of fibrosis compared with placebo in phase II double-blind, randomized trial.(62) Other potential candidates for effective steatohepatitis treatment include resmetirom, a selective thyroid h…”
BackgroundThe pathophysiology of MASLD: an immunometabolic perspective
Schwärzler, J., Grabherr, F., Grander, C., Adolph, T. E., & Tilg, H. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2294046 · Cited by 117
“Several agents are currently being tested to reduce lipotoxicity and metabolic changes in MASLD, including DNL-inhibitors, fibroblast growth factor (FGF)19 and FGF21 analogues or peroxisome proliferator-activated receptor (PPAR) agonists [102,103].”
Loomba, R., Lawitz, E. J., Frias, J. P., Ortiz-Lasanta, G., Johansson, L., Franey, B. B., Morrow, L., Rosenstock, M., Hartsfield, C. L., Chen, C.-Y., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00347-8 · Cited by 106
Self-citationCiardullo, S., Muraca, E., Vergani, M., Invernizzi, P., & Perseghin, G. (2023) · Gastroenterology report · doi:10.1093/gastro/goae029 · Cited by 121
“…trial involving 247 patients with “at-risk NASH,” it showed significant improvements in NASH resolution without worsening of fibrosis at Week 24 (achieved by 49% and 39% of patients treated with 1,200 and 800mg of lanifibranor, respectively, compared with 22% of patients in the placebo group) [89].”
ResultBarb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Dzen, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.045 · Cited by 116
Self-citationZhang, X., Lau, H. C.-H., & Yu, J. Q. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100018 · Cited by 112
Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96
Self-citationThe Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., & An, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294267 · Cited by 111
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 106
Fan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 152
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Zhao, Y., Zhou, Y., Wang, D., Huang, Z., Xiao, X., Zheng, Q., Li, S., Long, D., & Feng, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417514 · Cited by 100
“Sven Francque. et al. found that in MASH patients, the expression of PPAR α was significantly downregulated, and in MASH mice fed a diet lacking methionine choline (MCDD), a decrease in PPAR α led to an aggravated degree of hepatitis [100].”
BackgroundWhy Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Self-citationAltered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 103
“The Phase IIb trial results showed significant improvements in hepatic steatosis, inflammation, and fibrosis [123].”
Yan, M., Cui, Y., & Xiang, Q. (2025) · Theranostics · doi:10.7150/thno.106597 · Cited by 95
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
Management of NAFLD in primary care settings
Wong, V. W. S., Zelber‐Sagi, S., Cusi, K., Carrieri, P., Wright, E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 81
Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 92
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
“Francque et al. (2021) reported a 3% increase in body weight in both the low-and high-dose treatment group of the phase 2 NATIVE trial [20].”
Møllerhøj, M. B., Veidal, S. S., Thrane, K. T., Oró, D., Overgaard, A., Salinas, C. G., Madsen, M. R., Pfisterer, L., Vyberg, M., Simon, E., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13235 · Cited by 82
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Newsome, P. N., & Loomba, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186425 · Cited by 90
“%) for the higher dose of 1200 mg (35).”
Self-citationImmunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.